Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Visceral Leishmania donovani infection in interleukin-13-/- mice.

Literature DB >> 16552085

Visceral Leishmania donovani infection in interleukin-13-/- mice.

Henry W Murray¹, Christine W Tsai, Jianguo Liu, Xiaojing Ma.

Abstract

Leishmania donovani-infected interleukin-13-/- BALB/c mice showed impaired initial gamma interferon secretion and incomplete granuloma assembly at parasitized liver foci. Nonetheless, control of early parasite replication, resolution of liver infection, and responsiveness to antileishmanial chemotherapy were intact. By itself, interleukin-13 does not appear to materially influence acquired resistance in this intracellular infection.

Entities: Disease Gene Species

Mesh：

Substances：
Cytokines
Interleukin-13

Year: 2006 PMID： 16552085 PMCID： PMC1418934 DOI： 10.1128/IAI.74.4.2487-2490.2006

Source DB: PubMed Journal: Infect Immun ISSN： 0019-9567 Impact factor: 3.441

26 in total

1. Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation.

Authors: H W Murray
Journal: Infect Immun Date: 2000-11 Impact factor: 3.441

2. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis.

Authors: J Alexander; K C Carter; N Al-Fasi; A Satoskar; F Brombacher
Journal: Eur J Immunol Date: 2000-10 Impact factor: 5.532

Review 3. Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors: H W Murray
Journal: Antimicrob Agents Chemother Date: 2001-08 Impact factor: 5.191

4. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis.

Authors: H W Murray; C Montelibano; R Peterson; J P Sypek
Journal: J Infect Dis Date: 2000-10-09 Impact factor: 5.226

5. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors: Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal: Infect Immun Date: 2005-07 Impact factor: 3.441

6. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.

Authors: A R Satoskar; S Rodig; S R Telford; A A Satoskar; S K Ghosh; F von Lichtenberg; J R David
Journal: Eur J Immunol Date: 2000-03 Impact factor: 5.532

7. IL-13 gene-deficient mice are susceptible to cutaneous L. mexicana infection.

Authors: M R Sosa; L E Rosas; A N McKenzie; A R Satoskar
Journal: Eur J Immunol Date: 2001-11 Impact factor: 5.532

8. IL-10 mediates susceptibility to Leishmania donovani infection.

Authors: M L Murphy; U Wille; E N Villegas; C A Hunter; J P Farrell
Journal: Eur J Immunol Date: 2001-10 Impact factor: 5.532

9. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis.

Authors: H W Murray; S Delph-Etienne
Journal: Infect Immun Date: 2000-01 Impact factor: 3.441

Review 10. Tissue granuloma structure-function in experimental visceral leishmaniasis.

Authors: H W Murray
Journal: Int J Exp Pathol Date: 2001-10 Impact factor: 1.925

14 in total

1. Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver.

Authors: Henry W Murray; Andrew D Luster; Hua Zheng; Xiaojing Ma
Journal: Infect Immun Date: 2016-12-29 Impact factor: 3.441

2. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.

Authors: Ranadhir Dey; Pradeep K Dagur; Angamuthu Selvapandiyan; J Philip McCoy; Poonam Salotra; Robert Duncan; Hira L Nakhasi
Journal: J Immunol Date: 2013-01-21 Impact factor: 5.422

3. Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.

Authors: Rajatava Basu; Suniti Bhaumik; Arun Kumar Haldar; Kshudiram Naskar; Tripti De; Syamal Kumar Dana; Peter Walden; Syamal Roy
Journal: Infect Immun Date: 2007-10-01 Impact factor: 3.441

4. TLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasis.

Authors: Subir Karmakar; Siddhartha Kumar Bhaumik; Joydeep Paul; Tripti De
Journal: PLoS Pathog Date: 2012-04-12 Impact factor: 6.823

5. Endogenous IL-13 plays a crucial role in liver granuloma maturation during Leishmania donovani infection, independent of IL-4Rα-responsive macrophages and neutrophils.

Authors: Emma McFarlane; Katharine C Carter; Andrew N McKenzie; Paul M Kaye; Frank Brombacher; James Alexander
Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226

6. Transcriptional profiling of the spleen in progressive visceral leishmaniasis reveals mixed expression of type 1 and type 2 cytokine-responsive genes.

Authors: Claudia M Espitia; Omar A Saldarriaga; Bruno L Travi; E Yaneth Osorio; Alvaro Hernandez; Mark Band; Mandakini J Patel; Audrie A Medina; Michael Cappello; Andrew Pekosz; Peter C Melby
Journal: BMC Immunol Date: 2014-11-26 Impact factor: 3.615

7. Splenic CD4+ T Cells in Progressive Visceral Leishmaniasis Show a Mixed Effector-Regulatory Phenotype and Impair Macrophage Effector Function through Inhibitory Receptor Expression.

Authors: Audrie A Medina-Colorado; Elvia Y Osorio; Omar A Saldarriaga; Bruno L Travi; Fanping Kong; Heidi Spratt; Lynn Soong; Peter C Melby
Journal: PLoS One Date: 2017-01-19 Impact factor: 3.240